Holen Sie sich die Stockscreener-App
39.77
4.01%
-1.66
Schlusskurs vom Vortag:
$41.43
Offen:
$40.86
24-Stunden-Volumen:
436.66K
Relative Volume:
1.09
Marktkapitalisierung:
$1.91B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-5.53%
1M Leistung:
+6.71%
6M Leistung:
+235.33%
1J Leistung:
+0.00%
1-Tages-Spanne:
$38.13
$41.83
1-Wochen-Bereich:
$38.13
$41.83
52-Wochen-Spanne:
$6.71
$43.29
Maze Therapeutics Inc Stock (MAZE) Company Profile
Firmenname
Maze Therapeutics Inc
Sektor
Branche
Telefon
(650) 850-5070
Adresse
171 OYSTER POINT BOULEVARD, SUITE 300, SOUTH SAN FRANCISCO
Vergleichen Sie MAZE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
MAZE
Maze Therapeutics Inc
|
39.77 | 1.99B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Maze Therapeutics Inc Stock (MAZE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-04 | Eingeleitet | Wells Fargo | Overweight |
| 2025-11-14 | Eingeleitet | Raymond James | Outperform |
| 2025-09-02 | Eingeleitet | BTIG Research | Buy |
| 2025-07-23 | Eingeleitet | H.C. Wainwright | Buy |
| 2025-07-08 | Eingeleitet | Wedbush | Outperform |
Maze Therapeutics Inc Aktie (MAZE) Neueste Nachrichten
Maze Therapeutics (NASDAQ:MAZE) Trading Down 4.9%Here's Why - MarketBeat
Amy Bachrodt Sells 5,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Amy Bachrodt Sells 10,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Harold Bernstein Sells 45,000 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Atul Dandekar Sells 72,400 Shares of Maze Therapeutics (NASDAQ:MAZE) Stock - Defense World
Maze Therapeutics (NASDAQ:MAZE) Insider Sells $2,936,544.00 in Stock - MarketBeat
Maze Therapeutics SVP, finance sells $606k in shares - Investing.com
Maze Therapeutics Insider Sold Shares Worth $1,825,355, According to a Recent SEC Filing - marketscreener.com
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Consensus Recommendation of "Buy" by Analysts - MarketBeat
Growth Recap: Is Maze Therapeutics Inc stock trading at a premium valuationEarnings Overview Summary & Free Real-Time Volume Trigger Notifications - moha.gov.vn
How Maze Therapeutics Inc. stock benefits from tech adoptionMACD Histogram Signals & Free Fast Track Wealth Growth - bollywoodhelpline.com
New way to pay for at‑home AI neurorehab aims to widen access - Stock Titan
We Think Maze Therapeutics (NASDAQ:MAZE) Can Easily Afford To Drive Business Growth - Yahoo Finance
FY2025 Earnings Estimate for MAZE Issued By Lifesci Capital - MarketBeat
Maze Therapeutics price target raised to $46 from $34 at Guggenheim - MSN
Fundamentals Check: How Maze Therapeutics Inc. stock benefits from tech adoptionWeekly Stock Recap & Expert Approved Trade Ideas - Улправда
Maze Therapeutics (NASDAQ:MAZE) Stock Rating Upgraded by Lifesci Capital - Defense World
Guggenheim Reaffirms Their Buy Rating on Maze Therapeutics, Inc. (MAZE) - The Globe and Mail
Guggenheim raises Maze Therapeutics stock price target to $46 on CKD program - Investing.com Canada
What sentiment indicators say about Maze Therapeutics Inc. stockEarnings Risk Summary & Community Shared Stock Ideas - DonanımHaber
Lifesci Capital Upgrades Maze Therapeutics (NASDAQ:MAZE) to Strong-Buy - MarketBeat
What dividend safety score for Maze Therapeutics Inc. stockWeekly Trade Analysis & Weekly Setup with High ROI Potential - Улправда
Leerink Partners raises Maze Therapeutics stock price target to $50 on AMKD study - Investing.com Canada
We're Not Worried About Maze Therapeutics' (NASDAQ:MAZE) Cash Burn - Sahm
Frazier Life Sciences Management L.P. Buys 438,274 Shares of Maze Therapeutics, Inc. $MAZE - MarketBeat
Relief Therapeutics and NeuroX Complete Business Combination and Form MindMaze Therapeutics - Yahoo Finance
Maze Therapeutics (NASDAQ:MAZE) Upgraded at Wall Street Zen - MarketBeat
Maze Therapeutics (NASDAQ:MAZE) Stock Price Down 6.2%Time to Sell? - MarketBeat
CW Advisors LLC Purchases Shares of 30,235 Maze Therapeutics, Inc. $MAZE - MarketBeat
Investment Report: How Maze Therapeutics Inc stock benefits from tech adoptionJuly 2025 Market Mood & Accurate Buy Signal Alerts - BỘ NỘI VỤ
Maze Therapeutics (MAZE) Price Target Increased by 11.37% to 44.12 - Nasdaq
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of "Buy" by Brokerages - MarketBeat
Maze Therapeutics, Inc. (NASDAQ:MAZE) Given Average Recommendation of “Buy” by Brokerages - Defense World
Wells Fargo Initiates Coverage of Maze Therapeutics (MAZE) with Overweight Recommendation - Nasdaq
Maze Therapeutics (NASDAQ:MAZE) Sets New 52-Week HighTime to Buy? - MarketBeat
Maze Therapeutics stock price target raised to $60 from $50 at H.C. Wainwright - Investing.com Canada
A significant driver of top-line growth: Maze Therapeutics Inc (MAZE) - setenews.com
MAZE Crosses Above Average Analyst Target - Nasdaq
Maze Therapeutics stock rating initiated at Overweight by Wells Fargo - Investing.com Canada
HC Wainwright & Co. Maintains Maze Therapeutics (MAZE) Buy Recommendation - Nasdaq
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026, driving major growth - TradingView
MAZE: Pivotal APOL1 kidney disease data and new phase 2 studies are set for 2026 - TradingView
Maze Therapeutics (MAZE) Stock Analysis Report | Financials & Insights - Benzinga
Virtus Investment Advisers LLC Invests $85,000 in Maze Therapeutics, Inc. $MAZE - MarketBeat
Ensign Peak Advisors Inc Buys Shares of 18,539 Maze Therapeutics, Inc. $MAZE - Defense World
Maze Therapeutics stock hugs flat line following $140M IPO - MSN
Technical Analysis of Maze Therapeutics, Inc. (NASDAQ:MAZE) - TradingView
Will Maze Therapeutics Inc. stock sustain high P E ratiosTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Will Maze Therapeutics Inc. stock benefit from commodity pricesAnalyst Upgrade & Verified Swing Trading Watchlists - newser.com
Maze Therapeutics (NASDAQ:MAZE) Stock Price Up 8.4%Should You Buy? - MarketBeat
Price action breakdown for Maze Therapeutics Inc.2025 Stock Rankings & High Yield Equity Trading Tips - newser.com
Finanzdaten der Maze Therapeutics Inc-Aktie (MAZE)
Es liegen keine Finanzdaten für Maze Therapeutics Inc (MAZE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Maze Therapeutics Inc-Aktie (MAZE) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Dandekar Atul | CSBO |
Dec 30 '25 |
Option Exercise |
10.42 |
100 |
1,042 |
10,603 |
| Dandekar Atul | CSBO |
Dec 29 '25 |
Sale |
40.56 |
72,400 |
2,936,763 |
10,503 |
| Dandekar Atul | CSBO |
Dec 30 '25 |
Sale |
40.36 |
100 |
4,036 |
10,503 |
| Bernstein Harold | President, R&D & CMO |
Dec 29 '25 |
Option Exercise |
10.42 |
45,000 |
468,900 |
45,000 |
| Bernstein Harold | President, R&D & CMO |
Dec 29 '25 |
Sale |
40.56 |
45,000 |
1,825,355 |
0 |
| Bachrodt Amy | SVP, Finance |
Dec 29 '25 |
Option Exercise |
10.42 |
10,000 |
104,200 |
22,965 |
| Bachrodt Amy | SVP, Finance |
Dec 30 '25 |
Option Exercise |
10.42 |
5,000 |
52,100 |
17,965 |
| Bachrodt Amy | SVP, Finance |
Dec 29 '25 |
Sale |
40.58 |
10,000 |
405,766 |
12,965 |
| Bachrodt Amy | SVP, Finance |
Dec 30 '25 |
Sale |
40.08 |
5,000 |
200,407 |
12,965 |
0.57%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):